Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Amgen Inc, Pfizer, Inc, and Takeda Oncology.

Community Practice Connections™ Case Studies in AYA and Adult Acute Lymphoblastic Leukemia – How the Experts Think & Treat

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

Community Practice Connections Case Studies in AYA and Adult Acute Lymphoblastic Leukemia – How the Experts Think & Treat consists of a series of interactive clinical vignettes, short video interviews of leading experts in leukemia, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Benefits of Participating

  • Learn about emerging strategies for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
  • See how experts evaluate and manage measurable/minimal residual disease (MRD)
  • Discuss state-of-the-art management of patients with Ph-positive ALL

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen Inc, Pfizer, Inc, and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals interested in the latest advances in the treatment of patients with acute lymphoblastic leukemia. Fellows, researchers, nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment of patients with ALL are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Outline risk stratification strategies in ALL to help develop appropriate treatment plans through cytogenetic and immunophenotypic studies
  • Evaluate the clinical utility of MRD assessment and how this may inform prognosis and treatment planning for adolescent/young adult populations and adults with ALL
  • Define the role of emerging therapies for the management of ALL, including monoclonal antibodies, antibody–drug conjugates, and chimeric antigen receptor T-cell therapies
  • Recognize groups of patients who may be eligible for emerging ALL treatment approaches

Faculty, Staff, and Planners’ Disclosures


Elias Jabbour
Elias Jabbour, MD
Professor of Medicine
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Amgen, Pfizer, Takeda Pharmaceutical Co, Adaptive Biotechnologies, Novartis Pharma, Spectrum Pharmaceuticals, AbbVie Inc, Bristol-Myers Squibb.

Nicola Gökbuget
Nicola Gökbuget, MD
Head of Study Center
Department of Medicine II, Hematology/Oncology
Goethe University Hospital
Frankfurt, Germany

Disclosures: Grant Research Support: Amgen, Novartis, Pfizer, Jazz, Servier; Consultant: Amgen, Novartis, Pfizer, Servier, Gilead, Kite, Jazz.

Stephan A. Grupp
Stephan A. Grupp, MD, PhD
Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Chief, Cellular Therapy and Transplant Section
Director, Cancer Immunotherapy Program
Director, Translational Research for the Center for Childhood Cancer Research
Medical Director, Stem Cell Laboratory
Children’s Hospital of Philadelphia
Philadelphia, PA

Disclosures: Grant Research Support: Novartis, Servier, Kite; Consultant: Novartis, Roche, GSK, Cure Genetics, Humanigen, CBMG; Other: Study Steering Committee or Scientific Ad Board: Jazz, Adaptimmune, TCR2, Eureka, Cellectis, Juno, Vertex.

Dieter Hoelzer
Dieter Hoelzer, MD, PhD
Emeritus Director of Internal Medicine
University of Frankfurt
Frankfurt, Germany

Disclosures: Consultant: DKMS, GBG-IDMC, Juno-Celgene, IEO-SAB; Speakers Bureau: Servier Laboratories, Amgen, Medac, Juno-Celgene.

Hagop M. Kantarjian
Hagop M. Kantarjian, MD
Professor and Chair, Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: no relevant financial relationships with commercial interest.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By